Connect with us

Technology

The Galien Foundation Announces 2026 Prix Galien UK Award Candidates for “Best Biotechnology Product,” “Best Digital Health Solution,” “Best Medical Technology,” “Best Pharmaceutical Product,” “Best Public Sector Innovation” and “Best Health Equity Innovation”

Published

on

— Winners to be Announced on 11th June at the Prix Galien UK Awards Ceremony in London

LONDON, May 12, 2026 /PRNewswire/ — The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, today announced the 2026 Prix Galien UK Award candidates for “Best Biotechnology Product,” “Best Digital Health Solution,” “Best Medical Technology,” “Best Pharmaceutical Product,” “Best Public Sector Innovation” and “Best Health Equity Innovation.” Winners will be selected by a committee of distinguished scientific leaders and announced during the Prix Galien UK Awards Ceremony, on 11th June at the Natural History Museum in London. To learn more and secure your ticket to the event, please visit our website here.

“Annually, the Prix Galien UK awards remind us that innovation in life sciences is not just about discovery, it’s about impact,” said Professor Sir Munir Pirmohamed, David Weatherall Chair of Medicine at the University of Liverpool and the NHS Chair of Pharmacogenetics, Chair of the Prix Galien UK Committee. “It is a privilege to return to this year’s Prix Galien UK Awards to recognise the latest cohort of innovators who embody the UK’s unwavering commitment to transforming scientific breakthroughs into better outcomes for patients, worldwide.”

The Prix Galien UK Awards Committee will be evaluating the innovation demonstrated throughout each product’s scientific development, clinical application, and utility. Further consideration is given to the insights it has advanced in biomedical science and the product’s tangible impact on human health.

“The Prix Galien stands as a global tribute to the power of human ingenuity in advancing health across the world,” said Bruno Cohen, Chairman of The Galien Foundation. “We look forward to continuing to honour those whose vision and dedication push the boundaries of medical progress as we approach the 2026 Prix Galien UK Awards.”

The 2026 Prix Galien UK Award Candidates are as follows:

Best Biotechnology Product (Candidates) 

Company

Product

Autolus Ltd

Aucatzyl

Kristal Biotech

Vyjuvek

Volition

Nu.Q® Vet Cancer Test

Best Digital Health Solution (Candidates) 

Company

Product

August International Limited

AI-Powered Real-time Telehealth Scheme

Evaxion

AI-Immunology™ platform

Evinova

Unified Trial Solution

Gulsine ltd.

A2P2 Platform

HARLEYDOC

HARLEYDOC APP

House of Possibility Limited
(TRADING AS RAPID TAPPING)

Rapid Tapping®

Otsuka Pharmaceuticals (UK) Ltd

Rejoyn

Perspectum

CoverScan

SökerData

SökerScan

Viscera Technologies Ltd

Quantico

Best Medical Technology (Candidates) 

Company

Product

MiniMed

MiniMed Go Smart MDI system

Novocure UK Limited

Optune Gio

Nyxoah SA

Genio

Smith & Nephew Medical Ltd.

RENASYS EDGE

THERMOTRAUMAPORT LTD

THERMOTRAUMAPORT

U-test diagnostics

U-test @ Home

Best Pharmaceutical Product (Candidates) 

Company

Product

AbbVie UK

Elahere®

Aventis Pharma (SANOFI)

TZIELD

Blueprint Medicines, a Sanofi company

Gilead Sciences Ltd

Sunlenca/Yeytuo

Incyte Biosciences UK Ltd

Opzelura® (ruxolitinib) 15 mg/g cream

Novartis Pharmaceuticals UK

Iptacopan▼

PhytoQuest Limited

Q-actin®

Servier Laboratories Ltd

Voranigo▼

Shionogi

Fetcroja

ViiV Healthcare

Apretude

Best Public Sector Innovation (Candidates) 

Company

Product

BioDundee

BioDundee’s Life Sciences and Healthcare Innovation Ecosystem

University College London Centre for Digital
Public Health in Emergencies (UCL dPHE)

Digital platform for vector-borne diseases (VBD) surveillance and early warning in Brazil and Madeira

University of Glasgow

Intensive low-calorie weight management programme to induce type 2 diabetes remission

University of Liverpool

Liverpool’s COVID-19 Trio: ISARIC (clinical characterisation), SMART (testing) and AGILE (trials)

University of Liverpool and Liverpool University
Hospitals NHS Foundation Trust

LDIR Tech

Well Cool Clothing Ltd

Well Cool Patient Wear

Best Health Equity Innovation (Candidates) 

Company

Product

Agios Pharmaceuticals, Inc.

Clinical Trials Designed with Patients, for Patients: RISE UP Sickle Cell Disease Clinical Program

Eli Lilly as the Sponsor in collaboration with 
North West e-Health, Health Innovation
Manchester and the University of Manchester

An open-label, pragmatic clinical trial in a UK real world setting in people living with obesity

HARLEY of LONDON

Harley Wellness Dollar Empowering Community Health, Wellness and Lifestyle

National Institute for Health and Care
Excellence (NICE)

NICE technology appraisal guidance (TA1044) for exagamglogene autotemcel (exa-cel) for
treating severe sickle cell disease in people 12 years and over. TA1044

Nuffield Department of Primary Care
Health Sciences University of Oxford

Centre for Research Equity through pharmacy, communities and healthcare

ProFactor Pharma

Affordable recombinant Factor VIII

Quercis Pharma AG

Kinisoquin™

Sisters of Support CIC

Sisters of Support

The Drug Discovery Unit, University of Dundee

Drug Discovery for Neglected Infectious Diseases

University of Glasgow

Enabling equitable access to lifesaving rabies post-exposure prophylaxis

The Prix Galien Awards were established in 1970 and launched in the UK in 1990 and have been awarded to 62 products since its inception. Winners are selected every year by the Prix Galien UK Awards Committee, which comprises 12 experts in the field, and includes a number of the UK’s leading luminaries in healthcare. The distinguished panel is guided by the conviction that acknowledging research-driven innovation is key to the improvement of healthcare in the UK and human health, globally.

During the ceremony, the 2026 Prix Galien UK Lifetime Achievement Award will be bestowed upon Dame Kate Bingham, Former Chair of the UK Government’s Vaccine Taskforce. The keynote address will be delivered by Dr John-Arne Røttingen, MD, PhD, CEO, Wellcome; Committee Member, Prix Galien Bridges.

Prix Galien UK Awards Committee 2026

Professor Sir Munir PIRMOHAMED
David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics
Committee Chair

Professor Jane ADAM
Honorary Professor, University of Exeter, Consultant Radiologist, St George’s Hospital London and former Chair Technology appraisal committee, NICE

Professor Bruce CAMPBELL
Past Chair NICE Interventional Procedures and Medical Technologies Advisory Committees; Honorary Vascular Consultant and Professor, Exeter

Alison CAVE, PhD
Chief Safety Officer, Medicines and Healthcare products Regulatory Agency (MHRA)

Professor Jesse DAWSON
Professor of Stroke Medicine at School of Cardiovascular and Metabolic Health in the College of Medical, Veterinary and Life Sciences at the University of Glasgow; Consultant Physician in the Queen Elizabeth University Hospital, Glasgow

Doctor Stephanie KUKU
Chief Knowledge Officer – Conceivable Life Sciences, Senior Consultant – Hardian Health, Board Trustee – The Kings Fund, Honorary Senior Research Fellow, UCL

Professor Sudhesh KUMAR, OBE
Vice President (Health), University of Warwick and President of Association of Innovation, Research and Technology Organisations, UK (AIRTO)

Professor Andrew MORRIS, CBE
Director, Health Data Research UK & Professor of Medicine and Vice Principal Data Science, University of Edinburgh

Professor Sharon PEACOCK, CBE
Master of Churchill College Cambridge

Professor Duncan RICHARDS
Professor of Clinical Therapeutics, University of Oxford

Doctor Lauren WALKER
Professor of Clinical Pharmacology & Therapeutics, University of Liverpool

Professor Dame Moira WHYTE
Sir John Crofton Professor of Respiratory Medicine, University of Edinburgh

About The Galien Foundation 
The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve human health. Its vision is to serve as a catalyst for the development of the next generation of treatments and technologies that will transform medical practice and save lives. Established in Paris in 1970 by Roland Mehl in honor of Galen, the father of medical science and modern pharmacology, the Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

Today, the Prix Galien operates in 16 countries across Africa, Europe, the United States and the UK. Expansion is currently underway in South Korea, Japan, Singapore, and Australia.

In 2025, the Foundation launched the inaugural Prix Galien Bridges Forum and Awards Ceremony at the Nobel Forum in Stockholm, spanning Northern and Southern Europe, Israel, and the Middle East, and the first-ever Patient Summit for Prix Galien USA, reinforcing its commitment to science without borders.

The Nobel Prize and the Prix Galien share a common birthplace in Paris, where Alfred Nobel signed his last will and testament in 1895. However, while the Nobel Prize in Physiology or Medicine recognises up to three individuals for specific discoveries, the Prix Galien honours the collaborative spirit and multidisciplinary progress that define modern biopharmaceutical innovation.

For more information, visit www.galienfoundation.org.

See the UK Hall of Fame: https://infogram.com/prix-galien-uk-since-1990-1hnp27e0qqyzn4g.

Follow the Foundation on social media:
https://www.facebook.com/GalienFoundation/ 
https://twitter.com/GalienFdn
https://www.linkedin.com/company/the-galien-foundation/

Media Contact (UK):
Julian Tyndale-Biscoe
Finn Partners
Julian.Tyndale-biscoe@finnpartners.com
+44 20 3217 7060

Media Contact (Global):
Kara Bradley
Finn Partners
Kara.Bradley@finnpartners.com
646-213-7243

Logo – https://mma.prnewswire.com/media/2592709/The_Galien_Foundation_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/the-galien-foundation-announces-2026-prix-galien-uk-award-candidates-for-best-biotechnology-product-best-digital-health-solution-best-medical-technology-best-pharmaceutical-product-best-public-sector-innovation-and–302768995.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Hexagon Composites ASA: Second quarter and half year 2026

Published

on

By

OSLO, Norway, Aug. 6, 2026 /PRNewswire/ — Hexagon Composites (OSE: HEX.OL), world leader in composite cylinder technology and related systems for storage and transportation of clean gaseous energy reported revenues of NOK 627 million for second quarter 2026 (Q2’25: 674 million). The reported EBITDA was NOK 69 million (Q2’25: NOK 12 million), resulting in an 11% EBITDA margin (Q2’25: 2%).

“We have spent the first half of the year delivering on what we promised,” said Philipp Schramm, CEO of Hexagon Composites. “We delivered a significant step up in profitability, supported by our successfully completed cost reduction program. We are also seeing positive traction across our core segments, and secured our largest order to date, establishing Mobile Pipeline technology as a key solution to support power generation for data centers.”

For 2026, half year revenues were NOK 1 296 (1 586) million, mainly driven by strength in the Fuel Systems segment, partially offset by muted Mobile Pipeline activity ahead of an activity spike in the second half of the year. The half year EBITDA totaled NOK 126 (56) million, resulting in a 10% EBITDA margin (Q2’25: 4%).

Outlook
Based on the progress delivered during the first half, the strengthening of our financial position, and improving visibility in our key markets, we are raising our full-year EBITDA guidance from above NOK 200 million to around NOK 300 million.

For further details, please see the attached second quarter and half year 2026 report and presentation.

Presentation of the results today at 08:30 am CEST
Philipp Schramm, CEO, and Eirik Løhre, CFO, will present the results at 08:30 am CEST today, broadcasted live via this link.

The presentation of the results will be a virtual event, followed by a Q&A session. The quarterly report, presentation, and webcast recording will be made available at www.hexagongroup.com.

For more information:
Eirik Løhre, CFO, Hexagon Composites
Telephone: +47 909 95 820 I eirik.lohre@hexagongroup.com

Berit-Cathrin Høyvik, Senior Director, Communications, Hexagon Composites
Telephone: +47 988 92 161 | berit-cathrin.hoyvik@hexagongroup.com

This information is considered to be inside information pursuant to the EU Market Abuse Regulation. This stock exchange release was published by Berit-Cathrin Høyvik, Sr. Director, Communications, Hexagon Composites ASA at the time and date provided.

About Hexagon Composites ASA
Hexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation, and conversion to clean energy in a wide range of mobility and industrial applications. Learn more at www.hexagongroup.com and follow @HexagonASA on LinkedIn.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hexagon-composites-asa/r/hexagon-composites-asa–second-quarter-and-half-year-2026,c4380468

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/hexagon-composites-asa-second-quarter-and-half-year-2026-302844604.html

Continue Reading

Technology

Full Ownership of JJ-LAPP: LAPP Group Unifies Southeast Asia Operations

Published

on

By

LAPP’s largest-ever acquisition pairs global engineering with regional agility to drive Southeast Asia’s next wave of connectivity.

SINGAPORE, Aug. 6, 2026 /PRNewswire/ — LAPP Group, a global leader in cable and connection technology, has completed its acquisition of JJ-LAPP. With this move, the German family-owned company unifies its operations across Southeast Asia under the singular LAPP brand identity.

Marking the largest acquisition in LAPP’s history, this milestone combines German engineering quality and innovation with JJ-LAPP’s established local footprint and entrepreneurial spirit to deliver state-of-the-art connectivity solutions across Southeast Asia.

The transaction represents the conclusion of an equal-share joint venture originally founded in 2004 with Jebsen & Jessen Group.  Over the past two decades, the partnership successfully grew JJ-LAPP from a small cable distributor into a premier regional connectivity solutions provider.

Approximately 350 team members will be fully integrated into LAPP’s global structure. They are joining a team of more than 5,700 colleagues around the globe with a strong local footprint throughout Asia. LAPP is dedicated to preserving JJ-LAPP’s deep local market knowledge while enhancing service capabilities for customers across Singapore, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.

Richard Lee, Chairman and CEO of Asia Pacific for LAPP Group, said: “Southeast Asia’s market diversity is its greatest strength, but beneath every thriving sector lies a common denominator: the critical need for advanced cables and connection technology.”

“Whether it’s accelerating the rapid expansion of regional data centers, automating factories, or building smarter infrastructure, reliable connectivity is non-negotiable. LAPP is proud to be at the heart of this evolution, delivering the German-engineered reliability needed to power the region’s next wave of sustainable growth.”

“Our customers are at the heart of all that we do. With this acquisition, we reinforce our commitment to the region and strengthen our support for Southeast Asian businesses with direct access to LAPP’s global supply chain and engineering expertise.”

The acquisition comes at a time when Southeast Asia is seeing significant investment in AI-driven data centers, automated manufacturing facilities, and renewable energy infrastructure. These developments are creating growing demand for specialized cable and connection solutions that can support high-performance applications while withstanding the region’s challenging tropical environments.

Asia-Pacific is already LAPP’s fastest growing region with a strong double-digit growth rate in fiscal year 2025. To drive this growth, LAPP will leverage Indonesia as a core regional manufacturing hub to shorten lead times, alongside Vietnam as a key commercial hub.

Customers across high-growth industries, including industrial automation, data centers, and renewable energy, will continue to experience seamless business continuity while benefiting from faster response times and deeper regional engineering support.

Press contact:

Tobias Matthieß
Specialist External
Communications
Phone: +49 711 78386213
Tobias.Matthiess@lapp.com

Lapp Holding SE
Schulze-Delitzsch-Str. 25 
DE-70565 Stuttgart

About LAPP: 

Headquartered in Stuttgart, Germany, LAPP is a leading supplier of integrated solutions and branded products in the field of cable and connection technology. The company’s portfolio includes standard and highly flexible cables, industrial connectors and screw technology, customised system solutions, automation technology and robotics solutions as well as technical accessories. LAPP’s core market is the industrial machinery and plant engineering sector. Other key markets are in the food industry, logistics, as well as the energy and the mobility sectors.

The company was founded in 1959 and is still fully family-owned today. In the 2025 fiscal year, it generated consolidated sales of EUR 1.93 billion. LAPP employs around 5,700 people worldwide, manufactures at 27 international locations and is active in a total of over 80 countries worldwide.

You can find more information on this topic here: https://www.lapp.com/en/de/news/presse/e/000143

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/full-ownership-of-jj-lapp-lapp-group-unifies-southeast-asia-operations-302838813.html

SOURCE LAPP Group

Continue Reading

Technology

Bitfire Group OTC Desk Surpasses $100 Million in Monthly Volume, Hits All-Time High in July

Published

on

By

HONG KONG, Aug. 6, 2026 /PRNewswire/ — Bitfire Group (01611.HK), a Hong Kong-listed regulated digital asset custodian, reported that its over-the-counter (OTC) trading desk surpassed $100 million in monthly volume for July, achieving a new all-time high with a 257% increase from June.

As a subsidiary of Bitfire Group, Bitfire Trust’s OTC desk recorded volume growth across every week of July compared with the same weeks in June, reflecting sustained momentum in institutional trading activity.

According to internal company data as of the end of July, Bitfire Group has onboarded 760 clients, representing a 46.5x increase in client numbers. The company’s pipeline of interested accounts has reached 1,644, reflecting a 53.8x growth rate. The client base is primarily composed of high-net-worth individuals, institutional investors, and listed companies.

“Over the past year, Bitfire has completed its upgrade from market recognition to business positioning. We have established a business system centered on digital asset private banking, covering trading, custody, asset management, structured products, and institutional services,” said Livio Weng, CEO of Bitfire Group.

As a regulated digital asset custodian listed on the Hong Kong Stock Exchange, Bitfire Group provides institutional clients with a secure and compliant gateway to digital asset markets. The company’s OTC desk offers deep liquidity and tailored execution for large-volume trades.

About Bitfire Group
Bitfire Group (01611.HK) is Asia-Pacific’s first private banking-level digital asset custodian. Listed on the Hong Kong Stock Exchange, the company provides regulated custody, OTC trading, and digital asset financial services to institutional clients.

View original content:https://www.prnewswire.com/news-releases/bitfire-group-otc-desk-surpasses-100-million-in-monthly-volume-hits-all-time-high-in-july-302844633.html

SOURCE Bitfire Group

Continue Reading

Trending